Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Peptides Biosimilars market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.5% during the forecast period.
This report presents the market size and development trends by detailing the Peptides Biosimilars market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Peptides Biosimilars market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Peptides Biosimilars industry and will help you to build a panoramic view of the industrial development.
Peptides Biosimilars Market, By Type:
Glucagon
Calcitonin
Peptides Biosimilars Market, By Application:
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Diseases
Some of the leading players are as follows:
Celltrion
Dr Reddy's Laboratories
Mylan
Stada Arzneimittel AG
Dr. Reddy's Laboratories
Amgen
Biocon
Pfizer
Teva Pahrmaceutical
Samsung Biologics
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Peptides Biosimilars Market: Technology Type Analysis
-
4.1 Peptides Biosimilars Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Peptides Biosimilars Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Glucagon
4.3.2 Calcitonin
5 Peptides Biosimilars Market: Product Analysis
-
5.1 Peptides Biosimilars Product Market Share Analysis, 2018 & 2026
-
5.2 Peptides Biosimilars Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Peptides Biosimilars Market: Application Analysis
-
6.1 Peptides Biosimilars Application Market Share Analysis, 2018 & 2026
-
6.2 Peptides Biosimilars Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Oncology
6.3.2 Chronic Diseases
6.3.3 Autoimmune Diseases
6.3.4 Blood Disorders
6.3.5 Growth Hormone Deficiency
6.3.6 Infectious Diseases
6.3.7 Other Diseases
7 Peptides Biosimilars Market: Regional Analysis
-
7.1 Peptides Biosimilars Regional Market Share Analysis, 2018 & 2026
-
7.2 Peptides Biosimilars Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Celltrion
9.1.1 Celltrion Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Dr Reddy's Laboratories
9.2.1 Dr Reddy's Laboratories Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Mylan
9.3.1 Mylan Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Stada Arzneimittel AG
9.4.1 Stada Arzneimittel AG Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Dr. Reddy's Laboratories
9.5.1 Dr. Reddy's Laboratories Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Amgen
9.6.1 Amgen Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Biocon
9.7.1 Biocon Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Pfizer
9.8.1 Pfizer Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Teva Pahrmaceutical
9.9.1 Teva Pahrmaceutical Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Samsung Biologics
9.10.1 Samsung Biologics Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
The List of Tables and Figures (Totals 66 Figures and 122 Tables)
Figure Glucagon Peptides Biosimilars market, 2015 - 2026 (USD Million)
Figure Calcitonin Peptides Biosimilars market, 2015 - 2026 (USD Million)
Figure Oncology market, 2015 - 2026 (USD Million)
Figure Chronic Diseases market, 2015 - 2026 (USD Million)
Figure Autoimmune Diseases market, 2015 - 2026 (USD Million)
Figure Blood Disorders market, 2015 - 2026 (USD Million)
Figure Growth Hormone Deficiency market, 2015 - 2026 (USD Million)
Figure Infectious Diseases market, 2015 - 2026 (USD Million)
Figure Other Diseases market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Peptides Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table North America Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table North America Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table North America Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Canada Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Canada Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Europe Peptides Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table Europe Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Europe Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Europe Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Germany Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Germany Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table France Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table France Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Italy Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Italy Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Spain Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Spain Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Peptides Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table China Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table China Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Japan Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Japan Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table India Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table India Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Peptides Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table MEA Peptides Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table MEA Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table MEA Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table MEA Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Peptides Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Peptides Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Peptides Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Celltrion Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dr Reddy's Laboratories Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Mylan Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Stada Arzneimittel AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dr. Reddy's Laboratories Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Amgen Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Biocon Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Teva Pahrmaceutical Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Samsung Biologics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
